KA Imaging Announces New Funding for Its Activities

Summation

  • INOVAIT is a pan-Canadian network funded by the Government of Canada and hosted at the Sunnybrook Research Institute with the objective of building a truly integrated image-guided therapy ecosystem, fueling continuous innovation that revolutionizes healthcare globally.
  • KA Imaging has also signed a strategic investment and technology development agreement with In-Q-Tel, the not-for-profit strategic investor that accelerates the development and delivery of cutting-edge technologies to the U.
  • “We are pleased to be part of the In-Q-Tel portfolio and look forward to expanding our relationship with IQT and its government partners”, said Amol Karnick, President and CEO of KA Imaging.

X-ray manufacturer KA Imaging announced today new funding for its activities. Both new investments focus on the Reveal™ 35C detector. In-Q-Tel, Inc. and INOVAIT are now part of the strong list of partners working with KA Imaging.

Spectral Imaging in the Emergency Department

One of the projects, “Single exposure Dual Energy Subtraction X-ray Device for Image Guided Therapy”, aims to use the Reveal 35C in the Emergency Room. KA Imaging, in partnership with Sunnybrook Research Institute, will obtain X-ray images from patients, and use it to develop new material separation imaging algorithms for real-time image-guided therapy applications.

Funding for this project was provided in part by INOVAIT through the Government of Canada’s Strategic Innovation Fund.

“We’re proposing a widely accessible and affordable solution to achieve improved soft tissue, bone and foreign object visibility, without added acquisition time or patient imaging dose,” explained Karim S. Karim, CTO of KA Imaging.

INOVAIT is a pan-Canadian network funded by the Government of Canada and hosted at the Sunnybrook Research Institute with the objective of building a truly integrated image-guided therapy ecosystem, fueling continuous innovation that revolutionizes healthcare globally. Through connecting, educating, and investing in the industry’s brightest minds and most promising ventures, INOVAIT will support and encourage collaborative development and the integration of artificial intelligence (AI) into medical technologies.

Accelerating innovation

KA Imaging has also signed a strategic investment and technology development agreement with In-Q-Tel, the not-for-profit strategic investor that accelerates the development and delivery of cutting-edge technologies to the U.S. intelligence and national security community and its allies.

“KA Imaging’s patented technology benefits application areas ranging from healthcare to non-destructive testing. Reveal’s unique energy subtraction capabilities and portability make it a solution that can be effectively and easily deployed in challenging environments,” said Michael Falcon, Investment Partner at In-Q-Tel.

“We are pleased to be part of the In-Q-Tel portfolio and look forward to expanding our relationship with IQT and its government partners”, said Amol Karnick, President and CEO of KA Imaging.

About Reveal 35C

Reveal™ 35C is a single exposure, portable, digital dual-energy subtraction (DES) X-ray detector. Powered by its exclusive SpectralDR™technology, it uses the same radiation dose as a traditional X-ray to create 3 different images without motion artifacts. In medical applications, this means a regular DR, plus a soft tissue and bone images. In the NDT market, Reveal’s energy subtraction capabilities can be translated into material differentiation, such as metals and plastics.

 

More News

Mira Pharmaceuticals Announces DEA Rules MIRA-55, a Novel Oral Pharmaceutical Marijuana Analog, Is Not Classified as a Controlled Substance

"We are thrilled with the DEA's decision, which underscores the potential of MIRA-55 as a groundbreaking therapeutic candidate," said Erez Aminov, Chairman & CEO of MIRA Pharmaceuticals. "This ruling allows us to focus on MIRA-55's unique cognitive and anxiety benefits. With access to $90B traditional neurological and $30B cannabis markets, MIRA-55 represents a significant value proposition for our company.  We remain committed to advancing it through the development pipeline for treating these diseases from which so many currently suffer."

Abu Dhabi Issues First BioTech Inventor-Class Golden Visa to Catalyze “Made-In-Abu-Dhabi IP” to Rockefeller University Inventor Dr Kambiz Shekdar, PhD

Dr Kambiz Shekdar said: "I gratefully take this opportunity as my solemn commitment to help build up the BioTech sector in Abu Dhabi with the same home-grown can-do-and-have-done record of accomplishment demonstrated by Emirati leadership, its people, and nation, and to do so collegially with the best of the best of the world's human capital across frontier technologies who, like myself, are drawn to the UAE with the thirst to pioneer and build better like only possible in the red-hot entrepreneurial climate of the UAE."

Activation Capital Introduces ‘Frontier BioHealth’ to Catalyze Life Science Startups

"We celebrate the growing base of research and technological advances within the region's health and life sciences sector," said Chandra Briggman, President and CEO of Activation Capital.

By using this website you agree to accept Medical Device News Magazine Privacy Policy